{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:20:21Z","timestamp":1783606821470,"version":"3.55.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006331","name":"Cancerop\u00f4le PACA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"name":"La ligue contre le cancer, INCa,"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Combination therapy in cancer treatment offers significant potential to overcome drug resistance, enhance efficacy, reduce toxicity, and expand drug indications. sorafenib, an FDA-approved multi-targeted kinase inhibitor, has demonstrated effectiveness across various cancers but currently lacks approved combination therapies. Recently, we identified LZX-2-73 as a promising drug candidate with potent anticancer activity, targeting the nuclear protein 1 (NUPR1), an emerging and promising target in cancer therapy. In this study, we report that the combination of the NUPR1 inhibitor LZX-2-73 with sorafenib produces strong synergistic anticancer effects in various cancer cell lines as well as in primary pancreatic ductal adenocarcinoma (PDAC) organoids. This combination significantly enhanced lactate dehydrogenase (LDH) release and caspase 3\/7 activity, markedly induced ROS accumulation, reduced the reduced\/oxidized glutathione ratio, and increased the accumulation of malondialdehyde (MDA) and lipid hydroperoxides. Collectively, the combination of LZX-2-73 and sorafenib led to a substantial increase in cell death due to massive oxidative stress. Additionally, in a pancreatic cancer xenograft mouse model, the combination of LZX-2-73 and sorafenib exhibited a synergistic anticancer effect, effectively inhibiting tumor growth. In summary, this study provides valuable insights into enhancing the anticancer activity of NUPR1 inhibitors through combination with sorafenib, offering a promising new avenue for cancer therapy and opening new indications.<\/jats:p>","DOI":"10.1038\/s41419-025-08178-8","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T15:26:50Z","timestamp":1763393210000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Synergistic antitumor activity of sorafenib and the NUPR1 inhibitor LZX-2-73 in multiple cancer models"],"prefix":"10.1038","volume":"16","author":[{"given":"Xi","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mat\u00edas","family":"Estaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8409-8485","authenticated-orcid":false,"given":"Emma","family":"Cosialls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2506-5567","authenticated-orcid":false,"given":"Patricia","family":"Santofimia-Casta\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1822-2237","authenticated-orcid":false,"given":"Juan","family":"Iovanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"8178_CR1","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41586-022-04437-2","volume":"603","author":"P Jaaks","year":"2022","unstructured":"Jaaks P, Coker EA, Vis DJ, Edwards O, Carpenter EF, Leto SM, et al. Effective drug combinations in breast, colon and pancreatic cancer cells. Nature. 2022;603:166\u201373.","journal-title":"Nature"},{"key":"8178_CR2","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.cell.2017.11.035","volume":"171","author":"JH Doroshow","year":"2017","unstructured":"Doroshow JH, Simon RM. On the design of combination cancer therapy. Cell. 2017;171:1476\u20138.","journal-title":"Cell"},{"key":"8178_CR3","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41573-022-00615-z","volume":"22","author":"H Jin","year":"2023","unstructured":"Jin H, Wang L, Bernards R. Rational combinations of targeted cancer therapies: background, advances and challenges. Nat Rev Drug Discov. 2023;22:213\u201334.","journal-title":"Nat Rev Drug Discov"},{"key":"8178_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3131-x","volume":"17","author":"B Laquente","year":"2017","unstructured":"Laquente B, Lopez-Martin J, Richards D, Illerhaus G, Chang DZ, Kim G, et al. A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients. BMC Cancer. 2017;17:137.","journal-title":"BMC Cancer"},{"key":"8178_CR5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s10637-013-0036-7","volume":"32","author":"C King","year":"2014","unstructured":"King C, Diaz H, Barnard D, Barda D, Clawson D, Blosser W, et al. Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor. Invest N Drugs. 2014;32:213\u201326.","journal-title":"Invest N Drugs"},{"key":"8178_CR6","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1016\/S2352-3026(24)00345-4","volume":"12","author":"JP Alderuccio","year":"2025","unstructured":"Alderuccio JP, Alencar AJ, Schatz JH, Kuker RA, Pongas G, Reis IM, et al. Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2025;12:e23\u201334.","journal-title":"Lancet Haematol"},{"key":"8178_CR7","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","volume":"391","author":"NC Turner","year":"2024","unstructured":"Turner NC, Im S-A, Saura C, Juric D, Loibl S, Kalinsky K, et al. Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer. N Engl J Med. 2024;391:1584\u201396.","journal-title":"N Engl J Med"},{"key":"8178_CR8","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/S1470-2045(23)00446-1","volume":"24","author":"L-AH Douma","year":"2023","unstructured":"Douma L-AH, Lalezari F, van der Noort V, de Vries JF, Monkhorst K, Smesseim I, et al. Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study. Lancet Oncol. 2023;24:1219\u201328.","journal-title":"Lancet Oncol"},{"key":"8178_CR9","doi-asserted-by":"publisher","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","volume":"66","author":"L Liu","year":"2006","unstructured":"Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, et al. Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5. Cancer Res. 2006;66:11851\u20138.","journal-title":"Cancer Res"},{"key":"8178_CR10","doi-asserted-by":"publisher","first-page":"65131","DOI":"10.1021\/acsami.4c11076","volume":"16","author":"Y Wu","year":"2024","unstructured":"Wu Y, Wang X, Li L, Wang M, Tian S, Song J, et al. Preparation of glutathione-regulated sorafenib targeted nanodrug delivery system and its antihepatocellular carcinoma activity. ACS Appl Mater Interfaces. 2024;16:65131\u201341.","journal-title":"ACS Appl Mater Interfaces"},{"key":"8178_CR11","doi-asserted-by":"publisher","first-page":"7453","DOI":"10.1002\/cam4.3389","volume":"9","author":"I El Dika","year":"2020","unstructured":"El Dika I, Capanu M, Chou JF, Harding JJ, Ly M, Hrabovsky AD, et al. Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib. Cancer Med. 2020;9:7453\u20139.","journal-title":"Cancer Med"},{"key":"8178_CR12","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060\u201372.","journal-title":"Cell"},{"key":"8178_CR13","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.cell.2017.09.021","volume":"171","author":"BR Stockwell","year":"2017","unstructured":"Stockwell BR, Angeli JPF, Bayir H, Bush AI, Conrad M, Dixon SJ, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171:273\u201385.","journal-title":"Cell"},{"key":"8178_CR14","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.cell.2013.12.010","volume":"156","author":"WS Yang","year":"2014","unstructured":"Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156:317\u201331.","journal-title":"Cell"},{"key":"8178_CR15","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.ccell.2019.04.002","volume":"35","author":"B Hassannia","year":"2019","unstructured":"Hassannia B, Vandenabeele P, Vanden Berghe T. Targeting ferroptosis to iron out cancer. Cancer Cell. 2019;35:830\u201349.","journal-title":"Cancer Cell"},{"key":"8178_CR16","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/s41556-024-01425-8","volume":"26","author":"T Nakamura","year":"2024","unstructured":"Nakamura T, Conrad M. Exploiting ferroptosis vulnerabilities in cancer. Nat Cell Biol. 2024;26:1407\u201319.","journal-title":"Nat Cell Biol"},{"key":"8178_CR17","doi-asserted-by":"publisher","first-page":"32360","DOI":"10.1074\/jbc.272.51.32360","volume":"272","author":"GV Mallo","year":"1997","unstructured":"Mallo GV, Fiedler F, Calvo EL, Ortiz EM, Vasseur S, Keim V, et al. Cloning and expression of the rat p8 cDNA, a new gene activated in pancreas during the acute phase of pancreatitis, pancreatic development, and regeneration, and which promotes cellular growth. J Biol Chem. 1997;272:32360\u20139.","journal-title":"J Biol Chem"},{"key":"8178_CR18","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.3390\/cells8111453","volume":"8","author":"P Santofimia-Casta\u00f1o","year":"2019","unstructured":"Santofimia-Casta\u00f1o P, Xia Y, Peng L, Vel\u00e1zquez-Campoy A, Abi\u00e1n O, Lan W, et al. Targeting the stress-induced protein NUPR1 to treat pancreatic adenocarcinoma. Cells. 2019;8:1453.","journal-title":"Cells"},{"key":"8178_CR19","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.canlet.2020.08.019","volume":"494","author":"A Murphy","year":"2020","unstructured":"Murphy A, Costa M. Nuclear protein 1 imparts oncogenic potential and chemotherapeutic resistance in cancer. Cancer Lett. 2020;494:132\u201341.","journal-title":"Cancer Lett"},{"key":"8178_CR20","doi-asserted-by":"publisher","first-page":"829","DOI":"10.4161\/cc.5.8.2686","volume":"5","author":"C Malicet","year":"2006","unstructured":"Malicet C, Dagorn JC, Neira JL, Iovanna JL. p8 and prothymosin alpha: unity is strength. Cell Cycle. 2006;5:829\u201330.","journal-title":"Cell Cycle"},{"key":"8178_CR21","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1073\/pnas.0508955103","volume":"103","author":"C Malicet","year":"2006","unstructured":"Malicet C, Giroux V, Vasseur S, Dagorn JC, Neira JL, Iovanna JL. Regulation of apoptosis by the p8\/prothymosin \u03b1 complex. Proc Natl Acad Sci USA. 2006;103:2671\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8178_CR22","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.1002\/jcp.22702","volume":"226","author":"MJ Sandi","year":"2011","unstructured":"Sandi MJ, Hamidi T, Malicet C, Cano C, Loncle C, Pierres A, et al. p8 Expression controls pancreatic cancer cell migration, invasion, adhesion, and tumorigenesis. J Cell Physiol. 2011;226:3442\u201351.","journal-title":"J Cell Physiol"},{"key":"8178_CR23","first-page":"1778","volume":"6","author":"AH Ree","year":"2000","unstructured":"Ree AH, Pacheco MM, Tvermyr M, Fodstad \u00d8, Brentani MM. Expression of a novel factor, com1, in early tumor progression of breast cancer. Clin Cancer Res. 2000;6:1778\u201383.","journal-title":"Clin Cancer Res"},{"key":"8178_CR24","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1002\/jcp.21889","volume":"221","author":"M Gironella","year":"2009","unstructured":"Gironella M, Malicet C, Cano C, Sandi MJ, Hamidi T, Tauil RMN, et al. p8\/nupr1 regulates DNA-repair activity after double-strand gamma irradiation-induced DNA damage. J Cell Physiol. 2009;221:594\u2013602.","journal-title":"J Cell Physiol"},{"key":"8178_CR25","doi-asserted-by":"publisher","first-page":"e1913","DOI":"10.1038\/cddis.2015.264","volume":"6","author":"LR Palam","year":"2015","unstructured":"Palam LR, Gore J, Craven KE, Wilson JL, Korc M. Integrated stress response is critical for gemcitabine resistance in pancreatic ductal adenocarcinoma. Cell Death Dis. 2015;6:e1913.","journal-title":"Cell Death Dis"},{"key":"8178_CR26","doi-asserted-by":"publisher","first-page":"e2269","DOI":"10.1038\/cddis.2016.175","volume":"7","author":"MR Emma","year":"2016","unstructured":"Emma MR, Iovanna JL, Bachvarov D, Puleio R, Loria GR, Augello G, et al. NUPR1, a new target in liver cancer: implication in controlling cell growth, migration, invasion and sorafenib resistance. Cell Death Dis. 2016;7:e2269.","journal-title":"Cell Death Dis"},{"key":"8178_CR27","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11060-016-2337-0","volume":"132","author":"J Li","year":"2017","unstructured":"Li J, Ren S, Liu Y, Lian Z, Dong B, Yao Y, et al. Knockdown of NUPR1 inhibits the proliferation of glioblastoma cells via ERK1\/2, p38 MAPK and caspase-3. J Neurooncol. 2017;132:15\u201326.","journal-title":"J Neurooncol"},{"key":"8178_CR28","first-page":"1240","volume":"33","author":"C Zeng","year":"2017","unstructured":"Zeng C, Yi B, Li X, Chen J. [Knockdown of nuclear protein 1 (NUPR1) gene inhibits proliferation and promotes apoptosis of human multiple myeloma U266 cells]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2017;33:1240\u20136.","journal-title":"Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi"},{"key":"8178_CR29","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.3727\/096504018X15188367859402","volume":"26","author":"C Zhou","year":"2018","unstructured":"Zhou C, Xu J, Lin J, Lin R, Chen K, Kong J, et al. Long noncoding RNA FEZF1-AS1 promotes osteosarcoma progression by regulating the miR-4443\/NUPR1 axis. Oncol Res. 2018;26:1335\u201343.","journal-title":"Oncol Res"},{"key":"8178_CR30","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1002\/ar.22571","volume":"295","author":"X Guo","year":"2012","unstructured":"Guo X, Wang W, Hu J, Feng K, Pan Y, Zhang L, et al. Lentivirus-mediated RNAi knockdown of NUPR1 inhibits human nonsmall cell lung cancer growth in vitro and in vivo. Anat Rec. 2012;295:2114\u201321.","journal-title":"Anat Rec"},{"key":"8178_CR31","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1136\/gutjnl-2013-305221","volume":"63","author":"CE Cano","year":"2014","unstructured":"Cano CE, Hamidi T, Garcia MN, Grasso D, Loncle C, Garcia S, et al. Genetic inactivation of Nupr1 acts as a dominant suppressor event in a two-hit model of pancreatic carcinogenesis. Gut. 2014;63:984\u201395.","journal-title":"Gut"},{"key":"8178_CR32","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.bbagen.2018.03.009","volume":"1862","author":"P Santofimia-Casta\u00f1o","year":"2018","unstructured":"Santofimia-Casta\u00f1o P, Rizzuti B, Abian O, Vel\u00e1zquez-Campoy A, Iovanna JL, Neira JL. Amphipathic helical peptides hamper protein-protein interactions of the intrinsically disordered chromatin nuclear protein 1 (NUPR1). Biochim Biophys Acta Gen Subj. 2018;1862:1283\u201395.","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"8178_CR33","doi-asserted-by":"publisher","first-page":"E6332","DOI":"10.1073\/pnas.1619932114","volume":"114","author":"P Santofimia-Casta\u00f1o","year":"2017","unstructured":"Santofimia-Casta\u00f1o P, Rizzuti B, Pey \u00c1L, Soubeyran P, Vidal M, Urrutia R, et al. Intrinsically disordered chromatin protein NUPR1 binds to the C-terminal region of Polycomb RING1B. Proc Natl Acad Sci USA. 2017;114:E6332\u201341.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8178_CR34","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.abb.2016.03.034","volume":"598","author":"JL Neira","year":"2016","unstructured":"Neira JL, Rizzuti B, Iovanna JL. Determinants of the pKa values of ionizable residues in an intrinsically disordered protein. Arch Biochem Biophys. 2016;598:18\u201327.","journal-title":"Arch Biochem Biophys"},{"key":"8178_CR35","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1172\/JCI127223","volume":"129","author":"P Santofimia-Casta\u00f1o","year":"2019","unstructured":"Santofimia-Casta\u00f1o P, Xia Y, Lan W, Zhou Z, Huang C, Peng L, et al. Ligand-based design identifies a potent NUPR1 inhibitor exerting anticancer activity via necroptosis. J Clin Invest. 2019;129:2500\u201313.","journal-title":"J Clin Invest"},{"key":"8178_CR36","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1007\/s00018-019-03347-3","volume":"77","author":"P Santofimia-Casta\u00f1o","year":"2020","unstructured":"Santofimia-Casta\u00f1o P, Rizzuti B, Xia Y, Abian O, Peng L, Vel\u00e1zquez-Campoy A, et al. Targeting intrinsically disordered proteins involved in cancer. Cell Mol Life Sci. 2020;77:1695\u2013707.","journal-title":"Cell Mol Life Sci"},{"key":"8178_CR37","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41420-021-00662-2","volume":"7","author":"C Huang","year":"2021","unstructured":"Huang C, Santofimia-Casta\u00f1o P, Liu X, Xia Y, Peng L, Gotorbe C, et al. NUPR1 inhibitor ZZW-115 induces ferroptosis in a mitochondria-dependent manner. Cell Death Discov. 2021;7:269.","journal-title":"Cell Death Discov"},{"key":"8178_CR38","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1158\/1078-0432.CCR-05-1700","volume":"12","author":"V Giroux","year":"2006","unstructured":"Giroux V, Malicet C, Barthet M, Gironella M, Archange C, Dagorn J-C, et al. p8 is a new target of gemcitabine in pancreatic cancer cells. Clin Cancer Res. 2006;12:235\u201341.","journal-title":"Clin Cancer Res"},{"key":"8178_CR39","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s44321-024-00032-2","volume":"16","author":"P Santofimia-Casta\u00f1o","year":"2024","unstructured":"Santofimia-Casta\u00f1o P, Fraunhoffer N, Liu X, Bessone IF, di Magliano MP, Audebert S, et al. Targeting NUPR1-dependent stress granules formation to induce synthetic lethality in KrasG12D-driven tumors. EMBO Mol Med. 2024;16:475\u2013505.","journal-title":"EMBO Mol Med"},{"key":"8178_CR40","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.canlet.2020.04.024","volume":"486","author":"W Lan","year":"2020","unstructured":"Lan W, Santofimia-Casta\u00f1o P, Xia Y, Zhou Z, Huang C, Fraunhoffer N, et al. Targeting NUPR1 with the small compound ZZW-115 is an efficient strategy to treat hepatocellular carcinoma. Cancer Lett. 2020;486:8\u201317.","journal-title":"Cancer Lett"},{"key":"8178_CR41","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.canlet.2021.07.026","volume":"519","author":"G Augello","year":"2021","unstructured":"Augello G, Emma MR, Azzolina A, Puleio R, Condorelli L, Cusimano A, et al. The NUPR1\/p73 axis contributes to sorafenib resistance in hepatocellular carcinoma. Cancer Lett. 2021;519:250\u201362.","journal-title":"Cancer Lett"},{"key":"8178_CR42","doi-asserted-by":"publisher","first-page":"14015","DOI":"10.18632\/aging.203012","volume":"13","author":"W He","year":"2021","unstructured":"He W, Cheng F, Zheng B, Wang J, Zhao G, Yao Z, et al. NUPR1 is a novel potential biomarker and confers resistance to sorafenib in clear cell renal cell carcinoma by increasing stemness and targeting the PTEN\/AKT\/mTOR pathway. Aging. 2021;13:14015\u201338.","journal-title":"Aging"},{"key":"8178_CR43","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1093\/bioinformatics\/btx162","volume":"33","author":"A Ianevski","year":"2017","unstructured":"Ianevski A, He L, Aittokallio T, Tang J. SynergyFinder: a web application for analyzing drug combination dose\u2013response matrix data. Bioinformatics. 2017;33:2413\u20135.","journal-title":"Bioinformatics"},{"key":"8178_CR44","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","volume":"13","author":"B Yadav","year":"2015","unstructured":"Yadav B, Wennerberg K, Aittokallio T, Tang J. Searching for drug synergy in complex dose\u2013response landscapes using an interaction potency model. Comput Struct Biotechnol J. 2015;13:504\u201313.","journal-title":"Comput Struct Biotechnol J"},{"key":"8178_CR45","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1038\/sj.onc.1202569","volume":"17","author":"EC LaCasse","year":"1998","unstructured":"LaCasse EC, Baird S, Korneluk RG, MacKenzie AE. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene. 1998;17:3247\u201359.","journal-title":"Oncogene"},{"key":"8178_CR46","doi-asserted-by":"publisher","first-page":"314","DOI":"10.7150\/jca.13332","volume":"7","author":"X Chen","year":"2016","unstructured":"Chen X, Duan N, Zhang C, Zhang W. Survivin and tumorigenesis: molecular mechanisms and therapeutic strategies. J Cancer. 2016;7:314\u201323.","journal-title":"J Cancer"},{"key":"8178_CR47","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.7150\/jca.105425","volume":"16","author":"C-H Lee","year":"2025","unstructured":"Lee C-H, Lin Y-C, Chang Y-C, Chen P-C, Lin K-H, Yeh T-M, et al. NUPR1 contributes to endocrine therapy resistance by modulating BIRC5 expression and inducing luminal B-ERBB2+ subtype-like characteristics in estrogen receptor-positive breast cancer cells. J Cancer. 2025;16:1694\u2013708.","journal-title":"J Cancer"},{"key":"8178_CR48","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.bcp.2011.04.011","volume":"82","author":"Y-S Kim","year":"2011","unstructured":"Kim Y-S, Jin H-O, Seo S-K, Woo SH, Choe T-B, An S, et al. Sorafenib induces apoptotic cell death in human non-small cell lung cancer cells by down-regulating mammalian target of rapamycin (mTOR)-dependent survivin expression. Biochem Pharmacol. 2011;82:216\u201326.","journal-title":"Biochem Pharmacol"},{"key":"8178_CR49","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/nrd2130","volume":"5","author":"S Wilhelm","year":"2006","unstructured":"Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006;5:835\u201344.","journal-title":"Nat Rev Drug Discov"},{"key":"8178_CR50","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","volume":"64","author":"SM Wilhelm","year":"2004","unstructured":"Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099\u2013109.","journal-title":"Cancer Res"},{"key":"8178_CR51","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1093\/jnci\/djj069","volume":"98","author":"F Carlomagno","year":"2006","unstructured":"Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM, et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst. 2006;98:326\u201334.","journal-title":"J Natl Cancer Inst"},{"key":"8178_CR52","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/bs.podrm.2018.11.003","volume":"44","author":"AA Abdelgalil","year":"2019","unstructured":"Abdelgalil AA, Alkahtani HM, Al-Jenoobi FI. Sorafenib. Profiles Drug Subst Excip Relat Methodol. 2019;44:239\u201366.","journal-title":"Profiles Drug Subst Excip Relat Methodol"},{"key":"8178_CR53","doi-asserted-by":"publisher","first-page":"6861","DOI":"10.1038\/sj.onc.1208841","volume":"24","author":"C Yu","year":"2005","unstructured":"Yu C, Bruzek LM, Meng XW, Gores GJ, Carter CA, Kaufmann SH, et al. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene. 2005;24:6861\u20139.","journal-title":"Oncogene"},{"key":"8178_CR54","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1158\/0008-5472.CAN-04-2423","volume":"65","author":"A Sharma","year":"2005","unstructured":"Sharma A, Trivedi NR, Zimmerman MA, Tuveson DA, Smith CD, Robertson GP. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res. 2005;65:2412\u201321.","journal-title":"Cancer Res"},{"key":"8178_CR55","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1358\/dot.2005.41.12.937959","volume":"41","author":"D Strumberg","year":"2005","unstructured":"Strumberg D. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today. 2005;41:773\u201384.","journal-title":"Drugs Today"},{"key":"8178_CR56","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1634\/theoncologist.2017-0168","volume":"22","author":"Y Patt","year":"2017","unstructured":"Patt Y, Rojas-Hernandez C, Fekrazad HM, Bansal P, Lee FC. Phase II trial of sorafenib in combination with capecitabine in patients with hepatocellular carcinoma: INST 08-20. Oncologist. 2017;22:1158\u2013e116.","journal-title":"Oncologist"},{"key":"8178_CR57","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920927602","volume":"12","author":"G Fan","year":"2020","unstructured":"Fan G, Wei X, Xu X. Is the era of sorafenib over? A review of the literature. Ther Adv Med Oncol. 2020;12:1758835920927602.","journal-title":"Ther Adv Med Oncol"},{"key":"8178_CR58","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13046-022-02567-z","volume":"42","author":"Y Li","year":"2023","unstructured":"Li Y, Yang W, Zheng Y, Dai W, Ji J, Wu L, et al. Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis. J Exp Clin Cancer Res. 2023;42:6.","journal-title":"J Exp Clin Cancer Res"},{"key":"8178_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2023.154668","volume":"111","author":"C Yang","year":"2023","unstructured":"Yang C, Lu T, Liu M, Yuan X, Li D, Zhang J, et al. Tiliroside targets TBK1 to induce ferroptosis and sensitize hepatocellular carcinoma to sorafenib. Phytomedicine. 2023;111:154668.","journal-title":"Phytomedicine"},{"key":"8178_CR60","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/hep.28251","volume":"63","author":"X Sun","year":"2016","unstructured":"Sun X, Ou Z, Chen R, Niu X, Chen D, Kang R, et al. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology. 2016;63:173\u201384.","journal-title":"Hepatology"},{"key":"8178_CR61","doi-asserted-by":"publisher","first-page":"e371","DOI":"10.1038\/oncsis.2017.65","volume":"6","author":"Z Fan","year":"2017","unstructured":"Fan Z, Wirth A-K, Chen D, Wruck CJ, Rauh M, Buchfelder M, et al. Nrf2-Keap1 pathway promotes cell proliferation and diminishes ferroptosis. Oncogenesis. 2017;6:e371.","journal-title":"Oncogenesis"},{"key":"8178_CR62","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.redox.2016.12.010","volume":"11","author":"J-L Roh","year":"2017","unstructured":"Roh J-L, Kim EH, Jang H, Shin D. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis. Redox Biol. 2017;11:254\u201362.","journal-title":"Redox Biol"},{"key":"8178_CR63","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202307273","volume":"20","author":"R Tong","year":"2024","unstructured":"Tong R, Feng X, Sun J, Ling Z, Wang J, Li S, et al. Co-delivery of siNRF2 and sorafenib by a \u201cclick\u201d dual functioned hyperbranched nanocarrier for synergistically inducing ferroptosis in hepatocellular carcinoma. Small. 2024;20:2307273.","journal-title":"Small"},{"key":"8178_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-021-03998-w","volume":"12","author":"J Zheng","year":"2021","unstructured":"Zheng J, Sato M, Mishima E, Sato H, Proneth B, Conrad M. Sorafenib fails to trigger ferroptosis across a wide range of cancer cell lines. Cell Death Dis. 2021;12:1\u201310.","journal-title":"Cell Death Dis"},{"key":"8178_CR65","first-page":"01162","volume":"S0891-5849","author":"P Cruz-Ojeda","year":"2024","unstructured":"Cruz-Ojeda P, de la, Navarro-Villar\u00e1n E, Fuertes-Agudo M, Mata A, L\u00f3pez-Lluch G, Navas P, et al. Peroxynitrite is involved in the mitochondrial dysfunction induced by sorafenib in liver cancer cells. Free Radic Biol Med. 2024;S0891-5849:01162\u20136.","journal-title":"Free Radic Biol Med"},{"key":"8178_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-20904-2","volume":"12","author":"J Liu","year":"2021","unstructured":"Liu J, Song X, Kuang F, Zhang Q, Xie Y, Kang R, et al. NUPR1 is a critical repressor of ferroptosis. Nat Commun. 2021;12:647.","journal-title":"Nat Commun"},{"key":"8178_CR67","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/hep.28574","volume":"64","author":"X Sun","year":"2016","unstructured":"Sun X, Niu X, Chen R, He W, Chen D, Kang R, et al. Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis. Hepatology. 2016;64:488\u2013500.","journal-title":"Hepatology"},{"key":"8178_CR68","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/cdd.2015.158","volume":"23","author":"Y Xie","year":"2016","unstructured":"Xie Y, Hou W, Song X, Yu Y, Huang J, Sun X, et al. Ferroptosis: process and function. Cell Death Differ. 2016;23:369\u201379.","journal-title":"Cell Death Differ"},{"key":"8178_CR69","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.201800311","volume":"19","author":"GC Forcina","year":"2019","unstructured":"Forcina GC, Dixon SJ. GPX4 at the Crossroads of Lipid Homeostasis and Ferroptosis. Proteomics. 2019;19:1800311.","journal-title":"Proteomics"},{"key":"8178_CR70","doi-asserted-by":"publisher","unstructured":"Lei P, Bai T, Sun Y Mechanisms of Ferroptosis And Relations With Regulated Cell Death: A Review. Front Physiol. 2019. https:\/\/doi.org\/10.3389\/fphys.2019.00139.","DOI":"10.3389\/fphys.2019.00139"},{"key":"8178_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112290","volume":"195","author":"A Garrido","year":"2020","unstructured":"Garrido A, Lepailleur A, Mignani SM, Dallemagne P, Rochais C. hERG toxicity assessment: useful guidelines for drug design. Eur J Med Chem. 2020;195:112290.","journal-title":"Eur J Med Chem"},{"key":"8178_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-79340-z","volume":"14","author":"X Liu","year":"2024","unstructured":"Liu X, Jimenez-Alesanco A, Li Z, Rizzuti B, Neira JL, Estaras M, et al. Development of an efficient NUPR1 inhibitor with anticancer activity. Sci Rep. 2024;14:29515.","journal-title":"Sci Rep"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08178-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08178-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08178-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T16:04:20Z","timestamp":1763395460000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08178-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8178"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08178-8","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"12 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A patent has been filed containing part of this study: PCT filing number n\u00b0 PCT\/EP2025\/053879, NUPR1 inhibitors for treating cancer. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. Ethical approval was obtained from the Animal Experimentation Ethics Committee No. 014, under the authorization number APAFIS#40941-2023021415217230 v4.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"During the preparation of this work, the author(s) used ChatGPT in order to correct the grammar of the text. After using this tool\/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of generative AI and AI-assisted technologies in the writing process"}}],"article-number":"839"}}